Hydromorphon Retard Hexal

Hydromorphone, the active ingredient in Hydromorphon Retard Hexal, is an opioid analgesic presented as an extended‑release oral tablet for oral use. It is indicated for the management of moderate to severe acute pain, postoperative pain, and cancer‑related pain in adult patients. The formulation provides prolonged plasma concentrations, allowing twice‑daily dosing in many treatment protocols.

GNH USA supplies Hydromorphon Retard Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Hydromorphon Retard Hexal, an opioid analgesic, is used in pain pathways that involve central mu‑opioid receptors. - Moderate to severe acute pain: provides sustained relief for intense short‑term pain episodes. - Postoperative pain: helps control pain after major surgical procedures. - Cancer pain: offers continuous analgesia for persistent malignant pain.

Hydromorphon Retard Hexal may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea: mild to moderate upset stomach. - Drowsiness: increased sedation. - Dry mouth: decreased salivation. - Sweating: excessive perspiration. - Itching: mild pruritus.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure. - Dependence or addiction: risk of misuse with prolonged use. - Allergic reactions: rash, angioedema, or anaphylaxis. - QT prolongation: cardiac conduction abnormalities. - Withdrawal syndrome: symptoms upon abrupt discontinuation after prolonged therapy.

When prescribing Hydromorphon Retard Hexal, clinicians should consider several safety measures. - Assess pain severity: confirm that opioid therapy is appropriate for the level of pain. - Evaluate respiratory function: avoid use in patients with compromised breathing. - Monitor for signs of dependence: watch for misuse or addiction behaviors. - Adjust for renal/hepatic impairment: dose may need modification in organ dysfunction. - Avoid concurrent CNS depressants: limit use with benzodiazepines or alcohol. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Hydromorphon Retard Hexal can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Other opioids: additive respiratory depression. - Benzodiazepines: heightened sedation and respiratory risk. - MAO inhibitors: potential for severe hypotension. - CNS depressants (e.g., antihistamines, muscle relaxants): increased drowsiness.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise hydromorphone levels. - CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect. - Anticholinergics: may exacerbate constipation. - Diuretics: can enhance orthostatic hypotension. - Serotonergic agents: risk of serotonin syndrome when combined with high‑dose opioids.